Pacific Biosciences of California, Inc.
$1.74
▼
-0.74%
2026-04-21 08:43:01
www.pacb.com
NMS: PACB
Explore Pacific Biosciences of California, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$510.38 M
Current Price
$1.74
52W High / Low
$2.73 / $0.85
Stock P/E
—
Book Value
$0.02
Dividend Yield
—
ROCE
-78.39%
ROE
-2.13%
Face Value
—
EPS
$-1.82
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
485
Beta
2.33
Debt / Equity
13,131.84
Current Ratio
5.15
Quick Ratio
4.47
Forward P/E
-3.25
Price / Sales
2.53
Enterprise Value
$827.59 M
EV / EBITDA
-4.89
EV / Revenue
5.17
Rating
Buy
Target Price
$2.58
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Leverage is relatively high.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | GE HealthCare Technologies Inc. | $71.58 | 15.76 | $32.85 B | 0.19% | 9.93% | 22.38% | $89.77 / $59.95 | $22.77 |
| 2. | Phaos Technology Holdings (Caym | $1.95 | — | — | — | 214.51% | -10.73% | $7.39 / $0.53 | $-0.06 |
| 3. | Electromed, Inc. | $25.4 | 23.98 | $215.65 M | — | 22.29% | 20.2% | $30.73 / $17.73 | $5.49 |
| 4. | Cytek Biosciences, Inc. | $4.57 | — | $592.62 M | — | -10.52% | -18.05% | $6.18 / $2.37 | $2.66 |
| 5. | Profound Medical Corp. | $7.15 | — | $331 M | — | -57.78% | -67.11% | $12.4 / $5.23 | $1.83 |
| 6. | LivaNova PLC | $65.81 | — | $3.6 B | — | 11.09% | -19.24% | $71.92 / $34 | $21.96 |
| 7. | Standard BioTools Inc. | $0.97 | — | $361.83 M | — | -20.31% | -13.13% | $1.72 / $0.87 | $1.23 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 44.65 M | 38.44 M | 39.77 M | 37.15 M | 39.22 M | — |
| Operating Profit | -41.2 M | -38.88 M | -44.85 M | -432.63 M | -63.68 M | — |
| Net Profit | -40.37 M | -38 M | -41.93 M | -426.07 M | 2.37 M | — |
| EPS in Rs | -0.13 | -0.13 | -0.14 | -1.41 | 0.01 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 160 M | 154.01 M | 200.52 M | 128.3 M |
| Operating Profit | -557.56 M | -290.66 M | -310.37 M | -304.82 M |
| Net Profit | -546.38 M | -309.85 M | -306.74 M | -314.25 M |
| EPS in Rs | -1.81 | -1.03 | -1.02 | -1.04 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 784.08 M | 1.26 B | 1.75 B | 1.77 B |
| Total Liabilities | 778.73 M | 753.85 M | 1.04 B | 1.2 B |
| Equity | 5.35 M | 506.59 M | 701.3 M | 562.9 M |
| Current Assets | 375.05 M | 495.68 M | 742.05 M | 852.07 M |
| Current Liabilities | 72.83 M | 66.3 M | 95.03 M | 263.33 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -111.21 M | -206.06 M | -259.17 M | -263.21 M |
| Investing CF | 115.45 M | 124 M | 4.6 M | 116.08 M |
| Financing CF | 3.43 M | -42.99 M | 108.89 M | 9.62 M |
| Free CF | -118.92 M | -212.25 M | -268.02 M | -280.14 M |
| Capex | -7.71 M | -6.19 M | -8.84 M | -16.93 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -23.19% | 56.29% | — | — |
| Earnings Growth % | -1.02% | 2.39% | — | — |
| Profit Margin % | -201.18% | -152.97% | -244.92% | — |
| Operating Margin % | -188.73% | -154.78% | -237.58% | — |
| Gross Margin % | 24.21% | 26.32% | 38.22% | — |
| EBITDA Margin % | -157.63% | -138.28% | -219.98% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.